## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL

OMB Number: Estimated average burden hours per response: 0.5

` ,				or Sect	on 30(h)	of the I	Investmen	t Com	npany Act	of 19	940						
1. Name and Address of Reporting Person*  Shaaltiel Yoseph				2. Issuer Name <b>and</b> Ticker or Trading Symbol Protalix BioTherapeutics, Inc. [ PLX ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year)								$\dashv$		w) ``	belov	(specify v)	
C/O PROTALIX BIOTHERAPEUTICS, INC.					04/14/2010									Executiv	e VP, R&D		
IT STREET	, SCIENCE PAF	RK, POB	455	4 15 4	1	. D-4	-	F:11	/A4====================================		>	1	to allocation at a		- Filia - (Oh - al-	A!:	
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
EL L3	3 2	20100											X Forr	n filed by On	e Reporting Per	son	
															re than One Re	porting	
(St	ate) (	Zip)											Pers	son			
	Tabl	e I - Noi	า-Deriv	ative Se	curitie	es Aco	quired,	Disp	osed o	of, o	r Bene	efici	ally Own	ed			
Date			e Exonth/Day/Year) if		xecution Date, any		Code (Instr.					nd Secur Benef Owne	ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								v	Amount		(A) or (D)	Price	Trans	action(s)		(Instr. 4)	
Common Stock 04/14/				/2010			S		1,309	(1)	1) D		7 8	82,445	D		
	Та																
Security or Exercise (Month/Day/Year) if any		Date,	Transaction Code (Insti	ransaction of Eode (Instr. Derivative (		Expiratio	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		str. 3	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
	(Final Stock	(First) (COTALIX BIOTHERAPEUT: IT STREET, SCIENCE PARELL L3 (State) (Cotation or Exercise Price of Derivative (Month/Day/Year)	(First) (Middle) DTALIX BIOTHERAPEUTICS, INC IT STREET, SCIENCE PARK, POB  EL L3 20100  (State) (Zip)  Table I - Not  Security (Instr. 3)  Stock  Table II - I ( 2. Conversion or Exercise Price of Derivative (Month/Day/Year) (Month/Day/Year)	(First) (Middle)  DTALIX BIOTHERAPEUTICS, INC.  IT STREET, SCIENCE PARK, POB 455  EL L3 20100  (State) (Zip)  Table I - Non-Deriv  Security (Instr. 3)  2. Transaction Date (Month/Itstate)  Conversion or Exercise Price of Derivative (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  [Stock] 3. Transaction Date (Month/Day/Year)	2. Issue Protal  (First) (Middle)  OTALIX BIOTHERAPEUTICS, INC.  IT STREET, SCIENCE PARK, POB 455  EL L3 20100  (State) (Zip)  Table I - Non-Derivative Security (Instr. 3)  Stock  Table II - Derivative Security (Instr. 3)  Table II - Derivative Security (Instr. 3)  Table II - Derivative Security (Instr. 3)  3. Transaction Date (Month/Day/Year)  Table II - Derivative Security (Instr. 3)  Table II - Derivative Security (Instr. 3)  3. Transaction Date (Instr. 3)  Table II - Derivative Security (Instr. 3)  Table II - Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security   Conversion or Exercise Price of Derivative Security	Conversion or Exercise Price of Derivative Security   Security	2. Issuer Name and Ticker or Trace Protalix BioTherapeutic  3. Date of Earliest Transaction (Mod/14/2010  3. Date of Earliest Transaction (Mod/14/2010  4. If Amendment, Date of Original  Table I - Non-Derivative Securities Acquired, (Month/Day/Year)  Table II - Derivative Securities Acquired, Date (Month/Day/Year)  Table II - Derivative Securities Acquired, Diate (e.g., puts, calls, warrants, options  Table II - Derivative Securities Acquired, Diate (Month/Day/Year)  3. Transaction Date (e.g., puts, calls, warrants, options  2. Table II - Derivative Securities Acquired, Diate (month/Day/Year)  3. Transaction Date (f.g., puts, calls, warrants, options)  2. Table II - Derivative Securities Acquired, Diate (month/Day/Year)  3. Transaction Date (f.g., puts, calls, warrants, options)  4. Transaction Code (instr. 8)  5. Number of Derivative Securities Acquired (Month/Day/Year)  6. Date Expiration (Month/Day/Year)  7. Transaction Date (Month/Day/Year)  8. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4	2. Issuer Name and Ticker or Trading S Protalix BioTherapeutics, I  3. Date of Earliest Transaction (Month/I 04/14/2010  3. Date of Earliest Transaction (Month/I 04/14/2010  4. If Amendment, Date of Original Filed  5. Table I - Non-Derivative Securities Acquired, Disponsor (Month/Day/Year)  Table I - Non-Derivative Securities Acquired, Disponsor (E.g., puts, calls, warrants, options, comparison of Execution Date, if any (Month/Day/Year)  2. Table II - Derivative Securities Acquired, Disponsor (E.g., puts, calls, warrants, options, comparison of Execution Date, if any (Month/Day/Year)  3. Table II - Derivative Securities Acquired, Disponsor (E.g., puts, calls, warrants, options, comparison of Execution Date, if any (Month/Day/Year)  4. If Amendment, Date of Original Filed  5. Transaction Date (Month/Day/Year)  6. Date Exercise (Month/Day/Year)  7. Transaction Code (Instr. 8)  8. Stock  6. Spiriation Date (Month/Day/Year)  8. Stock  9. Order (Month/Day/Year)  9. Order (Instr. 3, 4)  9. Order (Month/Day/Year)  9. Order (Instr. 3, 4)	Conversion or Exercise Price of Protection of Executity (Security (Security (Instr. 3))   Conversion or Exercise Price of Price	2. Issuer Name and Ticker or Trading Symbol Protalix BioTherapeutics, Inc. [PLX]  3. Date of Earliest Transaction (Month/Day/Year) 04/14/2010  Table I - Non-Derivative Securities Acquired, Disposed of, of Security (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of, or (e.g., puts, calls, warrants, options, convertible security  Table II - Derivative Securities Acquired, Disposed of, or (e.g., puts, calls, warrants, options, convertible security  Security  Table II - Derivative Securities Acquired, Disposed of, or (e.g., puts, calls, warrants, options, convertible security  Security  Table II - Derivative Securities Acquired, Disposed of, or (e.g., puts, calls, warrants, options, convertible security)  Security  Table II - Derivative Securities Acquired, Disposed of, or (e.g., puts, calls, warrants, options, convertible security)  Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, Securities Acquired (A) or Disposed of (D) (Inst	Protalix BioTherapeutics, Inc. [PLX]  Protalix BioTherapeutics, Inc. [PLX]  3. Date of Earliest Transaction (Month/Day/Year) 04/14/2010  4. If Amendment, Date of Original Filed (Month/Day/Year)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Benefication (Month/Day/Year)  (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  Stock  Date of Earliest Transaction (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Benefication (P.) (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Benefication (P.) (Month/Day/Year)  Table II - Derivative Securities Acquired (P.) (Month/Day/Year)  Applied Transaction Date (P.) (Month/Day/Year) (Month/Day/Year)  Table II - Derivative Securities Acquired (P.) (Month/Day/Year)	2. Issuer Name and Ticker or Trading Symbol Protalix BioTherapeutics, Inc. [PLX]   5 (()   1	Address of Reporting Person* al Yoseph  (First) (Middle)  OTALIX BIOTHERAPEUTICS, INC. IT STREET, SCIENCE PARK, POB 455  L L3 20100  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Month/Day/Year)  (Month/Day/Year)  Security (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  2. Issuer Name and Ticker or Trading Symbol (Check all ap X Dire X Dire X Dire X Defined (Month/Day/Year)  3. Date of Earliest Transaction (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  5. Relationsh (Check all ap X Dire X Defined (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  5. Amendment, Date of Original Filed (Month/Day/Year)  7. Transaction Code (Instr. 3, 1, 309(1))  8. Amount (A) or Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  2. Code v Amount (A) or Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  2. Transaction Date (Month/Day/Year)  6. Individual of Line)  7. Transaction Disposed of, or Beneficially Owned (p.g., puts, calls, warrants, options, convertible securities)  2. Code v Amount (A) or Disposed of, or Beneficially Owned (p.g., puts, calls, warrants, options, convertible securities)  2. Code (Instr. 3, 4)  6. Individual of Line)  7. Title and Amount of Security (Instr. 3)  8. Price of Derivative Security (Instr. 3)  8. Price of Derivative Security (Instr. 3)  8. Price of Disposed of (D) (Instr. 3, and 4)	2. Issuer Name and Ticker or Trading Symbol Protalix BioTherapeutics, Inc. [PLX]   5. Relationship of Reporting Person (Check all applicable)   X Director   X Officer (give title below)   Executive   Executiv	2. Issuer Name and Ticker or Trading Symbol   Protalix BioTherapeutics, Inc. [PLX]   S. Relationship of Reporting Person(s) to (Check all applicable)   X. Director 10%   Y. Director 10%   X.	

Date Exercisable

Expiration Date

## **Explanation of Responses:**

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

04/16/2010 /s/ Yossi Maimon, POA

\*\* Signature of Reporting Person Date

Number

of Shares

Title

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(D)